AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7524263
Drug: Freeze‐dried, sulfonated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze‐dried, sulfonated human immunoglobulin at 200 mg/kg per day for five consecutive days (group C)
Trial: 27259583
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (TCS) application via soak and smear (SS)
Trial: 27259583
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (TCS) application to dry skin
Trial: 7747682
Drug: d-sotalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-sotalol (200 mg/day)
Trial: 2117891
Drug: Intraperitoneal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal administration of recombinant interferon-beta (IFN-beta) at 6 x 10(6) units continuously for 14 days from the day of operation.
Trial: 12478216
Drug: Alcohol (0.80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.80 g/kg)
Trial: 28567578
Drug: Multiple-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, two boluses at 3 and 6 hours later (group A)
Trial: 28567578
Drug: Multiple-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, one bolus at 9 hours later (group B)
Trial: 26458939
Drug: Dalbavancin 500
RxNorm normalized name: dalbavancin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin 500 mg
Trial: 23433688
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of DHA
Trial: 23433688
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oil capsules
Trial: 21243486
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nasal nicotine
Trial: 11673582
Drug: Low-dose vigabatrin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vigabatrin (18-36 mg/kg/day)
Trial: 11673582
Drug: High-dose vigabatrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vigabatrin (100-148 mg/kg/day)
Trial: 11673582
Drug: High-dose vigabatrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vigabatrin
Trial: 11673582
Drug: Vigabatrin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (both doses)
Trial: 9502190
Drug: euglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: euglycaemic clamp [glucose 5 mmol L(‐1)]
Trial: 9502190
Drug: hyperglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperglycaemic clamp [glucose 15 mmol L(‐1)]
Trial: 9502190
Drug: euglycaemic hyperinsulinaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: euglycaemic hyperinsulinaemic clamp [glucose 5 mmol L(‐l)]
Trial: 9502190
Drug: intrajejunal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrajejunal infusion of lipid (Lipofundin medium‐chained triglyceride 10%)
Trial: 24604685
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) combined with methylprednisolone (MPred) - EPO dosage: 20,000 U/24 h, MPred dosage: 1,000 mg/24 h for five consecutive days.
Trial: 24604685
Drug: Methylprednisolone (MPred)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MPred) alone - MPred dosage: 1,000 mg/24 h for five consecutive days, placebo for EPO.
Trial: 20410083
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients (10 mg iron, 375 microg vitamin A, 4.2 mg zinc, 225 microg folic acid, 1.35 microg vitamin B-12 per child per day)
Trial: 16040923
Drug: iohexol [300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol [300 mg of iodine per milliliter]
Trial: 16040923
Drug: iodixanol [320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol [320 mg I/mL]
Trial: 16040923
Drug: iomeprol [350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol [350 mg I/mL]
Trial: 16040923
Drug: iomeprol [400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol [400 mg I/mL]
Trial: 3189898
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.3 mg
Trial: 10230955
Drug: Phentolamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (0.2 mg/kg) during cooling and rewarming periods of CPB
Trial: 6824358
Drug: Potent and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent and midstrength topical steroids
Trial: 6824358
Drug: Simple lubricating
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple lubricating agents
Trial: 6824358
Drug: Irradiated five
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated five times weekly
Trial: 6824358
Drug: Irradiated three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated three times weekly
Trial: 3902420
Drug: Aspartame (2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (2.7 g per day for 18 weeks)
Trial: 3902420
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical appearing capsules)
Trial: 30120406
Drug: Capsule vitamin
RxNorm normalized name: vitamin A Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule vitamin D (CG)
Trial: 22878647
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1,000 mg/day) and E (400 I.U./day) supplementation for 1 year
Trial: 22878647
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cholinergic medication only)
Trial: 9033826
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: Propofol then an epidural lumbar block with bupivacaine 0.25% (single shot) and continuous propofol i.v. infusion
Trial: 6394515
Drug: Cotrimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day for 7 days)
Trial: 6394515
Drug: Cefadroxil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil (500 mg twice a day for 7 days)
Trial: 30784788
Drug: Myofascial release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial release group (n=18) receiving four sessions of myofascial treatment, each lasting 40 minutes.
Trial: 21994966
Drug: DHEA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA treatment in PAI women
Trial: 10593367
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% (90 mg) once daily
Trial: 1711274
Drug: H1- +
RxNorm normalized name: Histamine H1 Receptor Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1- + H2- antagonists
Trial: 6363098
Drug: Terbutaline 1
RxNorm normalized name: terbutaline 1 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 1 mg from a pressurised aerosol
Trial: 6363098
Drug: Terbutaline 1
RxNorm normalized name: terbutaline 1 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 1 mg from a nebuliser
Trial: 6363098
Drug: Terbutaline 1
RxNorm normalized name: terbutaline 1 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 1 mg from a pressurised aerosol with a pear‐shaped, 750 ml spacer
Trial: 6363098
Drug: Terbutaline 1
RxNorm normalized name: terbutaline 1 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 1 mg from a nebuliser with Intermittent Positive Pressure Ventilation (I.P.P.V.)
Trial: 6363098
Drug: Terbutaline 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 4 mg from a nebuliser
Trial: 22958623
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (increasing doses to achieve target resting HR <70 beats per minute)
Trial: 22958623
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (increasing doses)
Trial: 16702899
Drug: Interactive Voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive Voice Response (IVR) administered Hamilton Depression Rating Scale (HAM-D) scores before randomization
Trial: 12806565
Drug: 12-g piracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-g piracetam infusion
Trial: 26876349
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement (n = 20)
Trial: 26876349
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement (n = 20)
Trial: 22377805
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (valgus knee brace, customised neutral foot orthoses, shoes designed for motion control)
Trial: 22377805
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (neutral knee brace, flat unsupportive foot orthoses, shoes with flexible mid‐sole)
Trial: 16318658
Drug: 2.3 mL
RxNorm normalized name: Evkeeza 345 MG in 2.3 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.3 mL of 0.5% levobupivacaine with fentanyl 15 microg
Trial: 16318658
Drug: 2.6 mL
RxNorm normalized name: gemcitabine 2 GM in 52.6 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6 mL of 0.5% levobupivacaine alone
Trial: 10797115
Drug: Carbohydrate ingestion
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate ingestion (CHO) - 250 ml of an 8% carbohydrate‐electrolyte solution every 15 min
Trial: 3496470
Drug: Three-day antibiotic
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day antibiotic treatment
Trial: 3496470
Drug: Suppressive antibiotics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive antibiotics, treatment of asymptomatic urinary tract infections, full course antibiotic therapy
Trial: 3496470
Drug: Placebo, treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, treatment of symptomatic urinary tract infection only, short course therapy
Trial: 25264990
Drug: Latanoprost/Timolol Fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost/Timolol Fixed Combination (LTFC)
Trial: 25264990
Drug: Latanoprost and
RxNorm normalized name: latanoprost and netarsudil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost and Timolol Gel-forming Solution Unfixed Combination (LTuFC)
Trial: 21319355
Drug: 0.25 μg.kg⁻¹
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 μg.kg⁻¹ remifentanil
Trial: 17046300
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 10 mg montelukast (M)
Trial: 29275582
Drug: Lansoprazole Capsules
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole Capsules + Mosapride Citrate + Shuganjieyu capsule
Trial: 29275582
Drug: Lansoprazole Capsules
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole Capsules + Mosapride Citrate + Deanxit + Shuganjieyu capsule
Trial: 29275582
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Lansoprazole Capsules + Mosapride Citrate)
Trial: 18374753
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vascular endothelial growth factor (VEGF) and L‐arginine (6 g per day for 3 months)
Trial: 2124732
Drug: Diazepam enema
RxNorm normalized name: diazepam Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam enema (0.5 mg/kg bodyweight) in lateral position
Trial: 6101337
Drug: H1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 plus H2 blocker (hydroxyzine HCl + cimetidine)
Trial: 7402688
Drug: H2 blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H2 blocker (cimetidine)
Trial: 28256066
Drug: nab-paclitaxel (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (150 mg/m2 once per week for 3 of 4 weeks)
Trial: 22209190
Drug: Aripiprazole 15
RxNorm normalized name: aripiprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 15 or 30 mg/day
Trial: 22209190
Drug: Lithium 900,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium 900, 1200 or 1500 mg/day
Trial: 19160399
Drug: Concurrent ESS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent ESS and CR
Trial: 10716064
Drug: Tiludronate 400
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiludronate 400 mg
Trial: 28087723
Drug: Prophylactic propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic propranolol (0.5 mg/kg/dose every 12 hours)
Trial: 27518319
Drug: Itopride 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 100 mg t.d.s.
Trial: 12430877
Drug: Total Therapy
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Therapy II (TT II) with thalidomide at a starting dose of 400 mg
Trial: 7039666
Drug: Oral timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral timolol (5 mg to 30 mg per day)
Trial: 7039666
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of timolol and adrenaline
Trial: 26408273
Drug: sulodexide 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulodexide 500 lipasemic units twice daily
Trial: 20924753
Drug: TFMPP (0.94
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFMPP (0.94 mg/kg, oral)
Trial: 19763062
Drug: Rub-and-spray method
RxNorm normalized name: betamethasone / gentamicin Topical Spray [Betagen brand of Betamethasone and Gentamicin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rub-and-spray method (group G, n=10)
Trial: 9786313
Drug: irinotecan 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 300 to 350 mg/m2 every 3 weeks
Trial: 28060148
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg ziv-aflibercept (0.08 mL) intravitreal injection
Trial: 26335105
Drug: Completion axillary
RxNorm normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion axillary treatment (completion axillary lymph node dissection or axillary radiation therapy)
Trial: 26335105
Drug: No completion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No completion axillary treatment
Trial: 21156974
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg (2 capsules) in recovery room, followed by celecoxib 200 mg (1 capsule) twice a day + placebo at bedtime for 3 days after surgery.
Trial: 21156974
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg (1 tablet) in recovery room, followed by 400 mg orally 3 times a day for 3 days after surgery.
Trial: 18987057
Drug: Low-dose infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose infusion (LDI)
Trial: 10488711
Drug: Alcohol intake
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol intake > or =30 g/d
Trial: 8729094
Drug: Diet rich
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet rich in n-6 linoleic acid or n-3 alpha-linolenic acid with or without fish oil supplements (n-3 derivatives)
Trial: 1908190
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and transcutaneous stimulation analgesia supplemented by small doses of fentanyl (mean 1.2 micrograms/kg, SD 1.7)
Trial: 1908190
Drug: Moderate-dose fentanyl
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose fentanyl anaesthesia (mean 22.9 micrograms/kg, SD 2.8)
Trial: 6580492
Drug: Acetylcysteine (N‐acetyl‐L‐cysteine)
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (N‐acetyl‐L‐cysteine) 1 hour before doxorubicin administration
Trial: 29967037
Drug: Self-management (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management (daily home BP monitoring and automated medication reduction via telemonitoring)
Trial: 16228107
Drug: Azathioprine (AZ)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZ) 2.5 mg/kg daily for 12 months, then 2 mg/kg daily
Trial: 10757579
Drug: Ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.1% with clonidine 2 microg/kg (1 ml/kg)
Trial: 3930128
Drug: 1.0 unit/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 unit/h aVP infusion
Trial: 29493395
Drug: Topical azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical azithromycin 15 mg/g ophthalmic solution, used twice a day for 3 days and then once a day until treatment completion (1 month).
Trial: 29493395
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin 250 mg tablets, 1×2 tablets (500 mg) on the first day, then 1×1 tablet (250 mg) for 4 days, with 3 cycles of treatment and 5-day intervals.
Trial: 24671897
Drug: Daily monitored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily monitored device-based parameters (heart rate, thoracic impedance, HR variability, physical activity)
Trial: 20182456
Drug: Valsartan/Hydrochlorothiazide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Hydrochlorothiazide combination (320/25 mg)
Trial: 15704683
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate supplement in Group I (n = 25)
Trial: 11809596
Drug: Benzoyl peroxide/erythromycin
RxNorm normalized name: BENZOYL PEROXIDE/ERYTHROMYCIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide/erythromycin combination (BP/E)
Trial: 10366088
Drug: Placebo DDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DDS (no active drug)
Trial: 10366088
Drug: DEX DDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX DDS (1 or 2 doses)
Trial: 7746691
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (n = 21), administered twice daily for 2 days
Trial: 7746691
Drug: Placebo (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (n = 19), administered twice daily for 2 days
Trial: 30615169
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral PrEP
Trial: 23920048
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of GnRH antagonist daily for 7 days
Trial: 23920048
Drug: Standard flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard flexible GnRH antagonist protocol
Trial: 19210631
Drug: Ghrelin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (40 microg) administered i.v. over 30 min
Trial: 19210631
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) administered i.v. over 30 min
Trial: 12768356
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 200 mg levodopa (LD)
Trial: 12768356
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 4 mg apomorphine (A)
Trial: 3950252
Drug: Cat allergen
RxNorm normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cat allergen treatment (15 with cat allergen)